Dimethylamine

Dimethylamine

SCHEMBL6718528

CCOc1ccc([N+](=O)[O-])cc1N.CNC

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.62
HTT P42858 2/20 0.51
MAPT P10636 6/20 0.51
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 3/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CYP3A4 P08684 2/20 0.50
TSHR P16473 1/20 0.50
NPBWR1 P48145 1/20 0.49
MCHR1 Q99705 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
USP2 O75604 1/20 0.49
RAB9A P51151 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TAAR1 Q96RJ0 1/20 0.48
MEN1 O00255 2/20 0.48
CREBBP Q92793 1/20 0.48
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700508 0.95 TDP1 (0.68) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL2084753 0.84 HTT (0.67) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL29469600 0.83 TDP1 (0.64) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL397794 0.83 TDP1 (0.64) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL11428399 0.82 TDP1 (0.59) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL11207238 0.82 TDP1 (0.67) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL11233176 0.82 TDP1 (0.67) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL700418 0.82 TDP1 (0.62) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL11428124 0.81 TDP1 (0.57) TDP1HTTMAPTALDH1A1KMT2A
SCHEMBL11232774 0.81 TDP1 (0.65) TDP1HTTMAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 TDP1 1239/4885HTT 284/4885MAPT 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.